treamid (XC268BG) / Pharmenterprises - LARVOL DELTA

Experimental Drugs in Randomized Controlled Trials for Long-COVID: What's in the Pipeline? A Systematic and Critical Review. (PubMed, Expert Opin Investig Drugs) - "Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention."

Journal • Review • CNS Disorders • Fatigue • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial. (PubMed, J Transl Med) - P2 | "4 weeks oral administration of 50 mg Treamid was associated with clinically significant improvement in the post-COVID patients, evident by an increase in FVC and/or DLCO as well as decreasing dyspnea. Treamid was well tolerated and can be safely administered to patients discharged after COVID. Treamid was more effective in women visible by superior improvement of COVID sequalae after 4 weeks treatment. Considering that female gender is a risk factor associated with the development of post-COVID symptoms, Treamid might offer a pharmacological treatment for long-term sequalae after COVID and supports further investigation in future clinical trials in post-COVID patients."

Clinical • Journal • P2 data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 (clinicaltrials.gov) - P2/3 | N=412 | Not yet recruiting | Sponsor: PHARMENTERPRISES LLC

New P2/3 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Lung Fibrosis after COVID-19: Treatment Prospects. (PubMed, Pharmaceuticals (Basel)) - "In this review, we analyze the latest data from ongoing clinical trials aimed at treating post-COVID lung fibrosis and analyze the rationale for the current drug candidates. We discuss the use of antifibrotic therapy for idiopathic pulmonary fibrosis, the IN01 vaccine, glucocorticosteroids as well as the stromal vascular fraction for the treatment and rehabilitation of patients with COVID-associated pulmonary damage."

Journal • Review • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=60; Completed; Sponsor: PHARMENTERPRISES LLC; Active, not recruiting ➔ Completed

Trial completion • Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis. (PubMed, Int J Mol Sci) - "Pirfenidone and nintedanib slow down but do not stop the progression of IPF...In this study, experiments were performed on male C57BL/6 mice with bleomycin-induced pulmonary fibrosis...Lastly, Treamid increases esterase activity and decreases apoptosis of CD31 lung cells in vitro. Based on these findings, we suggest that Treamid may represent a promising compound for the development of new antifibrotic agents, which are capable of stimulating regeneration of lung endothelium in IPF patients."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Metabolic Disorders • Respiratory Diseases • CD31

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=60; Active, not recruiting; Sponsor: PHARMENTERPRISES LLC; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: PHARMENTERPRISES LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: PHARMENTERPRISES LLC

New P2 trial • Fibrosis • Immunology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases